Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate ALN-6222 in Participants With Obesity
Sponsor: Alnylam Pharmaceuticals
Summary
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
88
Start Date
2026-06-03
Completion Date
2027-12-14
Last Updated
2026-06-03
Healthy Volunteers
No
Conditions
Interventions
ALN-6222
ALN-6222 will be administered subcutaneously (SC).
Placebo
Placebo will be administered SC.
Locations (1)
Clinical Trial Site
Mount Royal, Canada